Alli Vamsi, Rogers Ann M
Division of Minimally Invasive and Bariatric Surgery, Penn State Hershey Medical Center, 500 University Drive, Mail Code H-149, Hershey, PA, 17033, USA.
Curr Gastroenterol Rep. 2017 Jun;19(6):25. doi: 10.1007/s11894-017-0567-8.
Obesity is recognized as a chronic and recurring disease, often accompanied by other weight-related comorbid conditions such as obstructive sleep apnea, hypertension, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). This chapter will seek to focus on the effect of weight loss surgery (WLS), in particular Roux-en-Y gastric bypass (RYGB), on NAFLD.
Among several modalities available to treat NAFLD, the one most likely to achieve rapid, significant, and sustained improvement of liver disease is WLS. The most commonly studied WLS procedure at this time is RYGB, and there is significant evidence that this is a safe and effective procedure both for weight loss and to bring about improvement of multiple associated comorbid conditions, including NAFLD. Further research focusing on non-surgical approaches that might mimic the effect of WLS on liver pathology is needed.
肥胖被认为是一种慢性复发性疾病，常伴有其他与体重相关的合并症，如阻塞性睡眠呼吸暂停、高血压、2型糖尿病和非酒精性脂肪性肝病（NAFLD）。本章将重点关注减肥手术（WLS），特别是 Roux-en-Y 胃旁路术（RYGB）对NAFLD的影响。
在治疗NAFLD的几种可用方法中，最有可能实现肝病快速、显著和持续改善的是WLS。目前研究最多的WLS手术是RYGB，有大量证据表明，这是一种安全有效的手术，既能减肥，又能改善包括NAFLD在内的多种相关合并症。需要进一步研究可能模拟WLS对肝脏病理影响的非手术方法。
